Networks of Innovation: Vaccine Development at Merck, Sharp and Dohme, and Mulford, 1895-1995

Front Cover
Cambridge University Press, Aug 13, 1997 - Business & Economics - 273 pages
Networks of Innovation offers an historical perspective on the manner in which private-sector organizations have acquired, sustained, and periodically lost the ability to develop, manufacture, and market new serum antitoxins and vaccines. The primary focus is on the H.K. Mulford Company, on Sharp & Dohme, which acquired Mulford in 1929, and upon Merck & Co., Inc., which merged with Sharp & Dohme in 1953. By surveying a century of innovation in biologicals, the authors are able to analyze the conditions that either promoted or prevented creative changes in this important industry. They show how the activities of these three commercial enterprises were related to a series of complex, evolving networks of scientific, governmental, and medical institutions in the United States and abroad. This is the first such history to draw extensively on sources internal to Merck, one of the world's leading innovators in modern vaccines and pharmaceuticals.
 

What people are saying - Write a review

We haven't found any reviews in the usual places.

Selected pages

Contents

1894 The foremost medical question of the day
1
The Mulford Story
9
A Sharp Dohme Interlude
33
The Virology Network and a New Program at Merck Sharp Dohme
53
Hillemans Innovations First Phase
79
Dangerous Interlude
123
Transforming Bacteriology A Second Phase
151
New Networks New Leadership The Hepatitis B Vaccines
181
Vaccine Innovation in the Nineties New Strategies New Opportunities and Public Confrontations
211
Historical Perspectives on the Process of Innovation
241
Acknowledgments
253
A Word About Sources
257
Index
259
Copyright

Other editions - View all

Common terms and phrases